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Measuring total cell-free DNA (cfDNA) or cancer-specific mutations herein has presented as new tools in aiding the
treatment of cancer patients. Studies show that total cfDNA bears prognostic value in metastatic colorectal cancer
(mCRC) and that measuring cancer-specific mutations could supplement biopsies. However, limited information is
available on the performance of different methods. Blood samples from 28 patients with mCRC and known KRAS
mutation status were included. cfDNA was extracted and quantified with droplet digital polymerase chain reaction
(ddPCR) measuring Beta-2 Microglobulin. KRAS mutation detection was performed using ddPCR (Bio-Rad) and next-
generation sequencing (NGS, Ion Torrent PGM). Comparing KRAS mutation status in plasma and tissue revealed
concordance rates of 79% and 89% for NGS and ddPCR. Strong correlation between themethods was observed. Most
KRAS mutations were also detectable in 10-fold diluted samples using the ddPCR. We find that for detection of KRAS
mutations in ctDNA ddPCR was superior to NGS both in analysis success rate and concordance to tissue. We further
present results indicating that lower amount of plasma may be used for detection of KRASmutations in mCRC.
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irculating cell-free DNA (cfDNA) present in blood and other body
ids has initiated a new era in cancer diagnosis and treatment.
poptotic and necrotic cells from the entire body is the primary
urce of cfDNA (reviewed by Thierry et al. [1]), and total levels of
DNA are found to be increased in various cancers [2]. Circulating
mor DNA (ctDNA) is the fraction of cfDNA originating from
mor cells, and ctDNA analyses enable detection of tumor-specific
utations in cfDNA. ctDNA has been estimated to contribute to
01%-93% of the total cfDNA [3,4], and ctDNA has been
ggested to reflect tumor burden [5–9]. Therefore, ctDNA analysis
s been proposed as a noninvasive strategy for gaining insights into
e tumor’s mutational profile.
Of particular interest is detection of KRAS, BRAF, and NRAS
utations in metastatic colorectal (mCRC) patients, as these are
sociated with intrinsic resistance to the anti-EGFR antibody
eatments offered to this patient group (reviewed by Misale et al.0]). Concordance rates of 80%-96% between KRAS mutations
entified in ctDNA analyses and biopsies have been observed
,11–18]. Next-generation sequencing (NGS) and polymerase chain
action (PCR)–based techniques for ctDNA analysis are continu-
sly being refined to accommodate the variety of mutations and the
w frequencies. Several different approaches have been investigated
accommodate the increasing request for a clinically applicabledd
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rformance on clinical material remains insufficient.
The aim of the present study was to evaluate and compare methods
ed for measuring KRASmutations in ctDNA from mCRC patients.
rther, in a clinical setting, sample material can be sparse. Therefore,
e present study also undertook the aim of investigating the
asibility of analyzing ctDNA from smaller plasma volumes.(T
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atient Samples
Plasma samples originate from a Danish cohort of mCRC patients
eated with irinotecan/cetuximab and everolimus according to a
osed clinical trial (NCT01387880). Primary data are to be
blished elsewhere. The KRAS tissue genotype was recovered from
tient files, but no other clinical data were used. KRAS tissue-
notype analysis was performed in a routine setting using
herascreen DXS KRAS mutation kit covering codon 12 and 13
iagen, Hilden, Germany). Blood samples were centrifuged at
00g for 15 minutes at 4°C. Plasma was collected and stored at −
°C until further use.
Two subcohorts were used for the current study. Cohort 1
cluded 28 plasma samples from patients with known KRAS
utations in tissue (mutation in codon 12 or 13). Cohort 2 included
plasma samples containing at least 2.2 ml plasma and randomly
osen among the available samples. Each sample was divided into a 2
l and a 200 μl portion, and extraction was performed on these
parately. Samples were used to study how extraction of cfDNA from
o different volumes affects the total cfDNA measurements. cfDNA
as extracted from plasma using the QIAamp Circulating Nucleic
cid Kit (Qiagen, Hilden, Germany) from a range of 1.5-2 ml plasma
r cohort 2 (see Supplementary Table 1) and from either 2 ml or 200
l for cohort 2 following manufacturer’s protocol. Samples were
uted in 100 μl (for 1.5-2 ml plasma samples) or 50 μl (for 200 μl
asma samples) elution buffer (supplied with the kit). cfDNA was
ozen at −80°C until further analysis.
After extraction of cfDNA, a 10-fold dilution was made from each
mple in cohort 1. Original and diluted samples were used for
aluating how dilution of samples affected the total cfDNA
easurements and how the Bio-Rad ddPCR assays performed.
roplet Digital PCR
Droplet digital PCRs (ddPCRs) were performed using 2X ddPCR
permix for Probes (no UTP, Bio-Rad), relevant assay (Bio-Rad),
d 5 μl cfDNA in a total reaction volume of 20 μl following
anufacturer’s recommendations. ddPCRs were performed using the
X200 Droplet Digital PCR System (Bio-Rad). Data analyses were
rformed as recommended by the manufacturer using the
uantaSoft Software version 1.7.4.
Total cfDNA was quantified using an assay targeting beta-2-
icroglobuline (B2M). Lymphocyte contamination of total cfDNA
as detected using an immunoglobulin gene specific assay (PBC) as
eviously described [21]. The assays were multiplexed on the ddPCR
atform. Information on assays for B2M and PBC quantification can
found in Supplementary Table 1.
The Bio-Rad KRAS PrimePCR ddPCR Mutation assays (Bio-Rad)
ere used for ddPCR (see Supplementary Table 2). The limit of
tection for the assays was determined as recommended by Milbury
d colleagues [22].Downloaded for Anonymous User (n/a) at BS - University of Copen
For personal use only. No other uses without permission. CddPCR analyses was performed in triplicates. Data from triplicates
ere merged in the QuantaSoft software and were used for further
alysis. Erroneous wells were not included in the merge.
ext-Generation Sequencing
Libraries were prepared using the Oncomine Solid Tumor DNA
t on 1.1-10 ng of cfDNA following manufacturer’s instructions
hermo Fisher Scientific). Amplicon sizes may be found in
pplementary Table 2. Sample concentrations were estimated
om the B2M measurements. NGS was performed using the Ion
hef Instrument and Ion Personal Genome Machine (PGM) System
hermo Fisher Scientific). Sequencing was performed using Ion 316
BC chips with eight cfDNA samples per chip.
Primary data processing was performed using the Torrent Suite
ftware (version 5.0.4) on aTorrent Server and the IonAmpliSeqColon
d Lung Cancer panel v2 template (Thermo Fisher Scientific). Variant
lling was performed using the Ion Reporter Software (version 5.0) and
eAmpliSeqCHPv2 peripheral/CTC/CFDNA single sample workflow
hermo Fisher Scientific). Reference and hotspot BED files were
placed with those supplied with the kit. Default settings were used.
quencing was considered successful if the mean sequencing depth was
000. If this criterion could not be met, the sample was disqualified.
alled variants were only accepted if AF ≥1%. For visualization and
anual inspection of variants, the Integrative Genomics Viewer (Broad
stitute) was used [23].
The median number of mapped reads per sample was 408,401.5
ange: 233,435-1,414,524), mean depth was 4066.5 (range: 2332-
,438), median uniformity was 100% (range: 94.31-100), and
edian reads on target were 94.5% (range: 90.3-98.8).
atistics
All statistics were performed using Stata 13 (StataCorp 2013).
atasets were tested for normality. If data were not normally
stributed, log-transformation (using the natural logarithm) was
rformed to achieve normality, and graphs were produced with log-
ansformed data. In the KRAS mutation analyses, the value 0 was
ven to wild-type samples. For these datasets, the value 1 was added
all results to enable log-transformation.
For comparing the data produced in this study, the guidelines for
mparing methods by Giavarina were used [24]. To test correlation
tween measurements, linear regression was performed. To test
reement between methods/measurements, Bland-Altman plots and
its of agreement (95% prediction intervals) were used. Results
om log-transformed data were back-transformed to achieve
eaningful median ratios.esults
DNA Analysis
All cfDNA samples from cohort 1were sequenced, and the analysis was
asible for 86% of the samples (24 of 28). Among the 24 sequenced
mples, there was a 79% (19 of 24) concordance between tissue and
DNA (see Table 1). For further information on the NGS analysis, see
pplementary Table 4. For samples where the tissue genotype was not
nfirmed, BAM files were visualized using IntegrativeGenomics Viewer,
d the mutation was identified in three additional samples (10, 11, 12).
ommon for these was low variant frequency. For sample 26, neither of
e mutations detected in tumor were found by NGS ctDNA analysis;
stead, a p.Gly12Ala mutation was detected.hagen from ClinicalKey.com by Elsevier on May 27, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
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Table 1. CtDNA Analysis
Sample
ID
Tissue
Genotype
NGS ddPCR-2 ml ddPCR-200 μl
AF (%) AF (%) Copies/ml AF (%) Copies/ml
1 p.Gly12Val 19.08 22.80 4114.00 22.10 4620.00
2 p.Gly12Ala 37.93 40.40 15708.00 39.80 14300.00
3 p.Gly13Asp 5.51 12.00 607.20 12.20 715.00
4 p.Gly13Asp 19.32 27.20 1848.00 26.50 1969.00
5 p.Gly12Val 1.75 2.40 180.40 1.60 132.00
6 p.Gly12Asp 14.24 26.80 5104.00 25.80 5573.33
7 p.Gly12Val 39.70 60.50 12430.00 60.60 9460.00
8 p.Gly12Ser 1.99 6.00 280.50 7.90 357.50
9 p.Gly13Asp 7.84 16.80 1848.00 15.00 1826.00
10 p.Gly12Ser 0.00 0.70 30.80 0.00 0.00
11 p.Gly12Asp 0.00 1.13 112.20 0.00 0.00
12 p.Gly13Asp 0.00 0.00 0.00 0.00 0.00
13 p.Gly13Asp 23.38 20.60 926.32 16.00 648.42
14 p.Gly12Ala 19.16 26.60 2917.89 25.60 2929.47
15 p.Gly12Val 31.11 44.10 7526.32 43.30 7410.53
16 p.Gly12Val 2.09 2.20 259.11 1.40 158.89
17 p.Gly13Asp a 7.55 NA NA
18 p.Gly12Asp NA 2.60 92.40 6.20 198.00
19 p.Gly12Val NA 15.20 2002.00 13.20 1628.00
20 p.Gly13Asp 20.91 31.30 11088.00 30.40 11550.00
21 p.Gly12Asp 33.36 54.81 255200.00 54.40 242115.80
22 p.Gly12Val 32.27 36.80 35288.00 35.90 33770.00
23 p.Gly12Asp NA 14.90 1650.00 13.10 1353.00
24 p.Gly12Val 3.56 8.30 682.00 7.80 759.00
25 p.Gly12Val 58.15 66.45 170720.00 NA
26 p.Gly12Ser 0.00 0.00 0.00 NA
p.Gly12Asp 0.00 0.00 0.00 NA
p.Gly12Ala b 31.68 35.70 40304.00 35.60 39930.00
27 p.Gly13Asp NA 13.10 875.60 11.10 957.00
28 p.Gly12Asp 0.00 0.00 0.00 0.00 0.00
Abbreviations: AF, allele frequency; ctDNA, circulating tumor DNA; ddPCR, droplet digital PCR;
NA, not available; NGS, next-generation sequencing.
a This mutation was revealed as a c.38_39delGCinsAT and not the expected c.38GNA by NGS. The
mutation was not investigated by ddPCR.
b The p.GlyAla was not detected by the tissue genotyping, but exclusively in the ctDNA analysis.
Figure 1. Comparison of the NGS and ddPCR ctDNA analyses. (A) Linea
0.91). Results related to the regression are presented below the graph.
1222 Measuring KRAS Mutations in Circulating Tumor DNA Demuth et al. Translational Oncology Vol. 11, No. 5, 2018
Downloaded for Anonymous User (n/a) at BS - University of Copen
For personal use only. No other uses without permission. CThe p.Gly13Asp mutation in sample 17 was revealed as a
38_39delGCinsAT and not the expected c.38GNA by NGS.
nfortunately, this was not detected in time to allow a change in
PCR assay, and ddPCR results are therefore unavailable. For the
vestigated samples, the ddPCR confirmed 89% (24 of 27) of the
ssue genotypes (Table 1). The ddPCR analysis confirmed the p.
ly12Ala mutation in sample 26. Further information on the ddPCR
alyses can be found in Supplementary Table 4.
omparison of KRAS Mutation Analyses on ctDNA
Among the 23 samples where both NGS and ddPCR results were
ailable, there was a 91% concordance between the methods (21 of 23,
e Table 1). The results obtained from NGS and ddPCR analyses were
mpared. Three ddPCR analyses were performed on sample 26, and all
alyses were included in the comparison. Only samples where methods
reed in either identifying or not identifying the mutation were included
=23). Good correlation between AFs obtained from the two analyses
as obtained (R2 values of 0.91, see Figure 1A). The Bland-Altman
alysis presented a mean difference of 6.61 [95% confidence interval
I): 0.3.69-9.52] and limits of agreement of 5.97-19.18. The 95%
ediction interval predicted that measured AFs in NGS versus ddPCR
uld vary, but the AFs did correlate to those of the NGS analysis.
RAS Mutation Detection in Small-Volume Samples
KRAS mutation detection was investigated in the diluted samples
om cohort 1 to determine if small-volume samples can be used for
is purpose. A total of 26 of 28 samples had available material for
lution. We found a 92% concordance with the analysis performed
the original samples (24 of 26, Table 1).
Prior to analysis the diluted samples, we tested how extraction of
DNA from two different plasma volumes influenced total cfDNAr regression from the comparison of NGS and ddPCR AFs (R2 =
(B) Bland-Altman plot of the differences (NGS (AF)− ddPCR (AF)).
hagen from ClinicalKey.com by Elsevier on May 27, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
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Translational Oncology Vol. 11, No. 5, 2018 Measuring KRAS Mutations in Circulating Tumor DNA Demuth et al. 1223easurement. The B2M-PBC multiplex ddPCR analysis was
rformed on the samples from cohort 2. Further information can
found in Supplementary Table 5. Three samples were PBC
sitive, and PBC exceeded 0.1% of the total cfDNA (see
pplementary Table 5); therefore, these were excluded from further
alysis. Comparison of the original and diluted samples resulted in a
edian ratio (B2M 2 ml/B2M 200 μl) of 1.15 (95% CI: 1.08-1.22),
d limits of agreement were 0.92-1.43, corresponding to a median
derestimation of 15% (95% CI: 8-23) of B2M in 200 μl samples
compared to 2 ml samples (Figure 2).
iscussion
the present study, we investigated two different methods, NGS and
PCR, for investigating KRAS mutations in ctDNA. We further
vestigated the possibility using ddPCR for KRAS detection in small-
lume samples.
We find that when considering the tissue as gold standard, concordance
tes of 79% and 89% for NGS and ddPCR were found. The
ncordance rates are similar to those found by others [6,11–18]. The
viation between tissue and plasma analyses may be explained by various
uses. First, the tissue biopsies were taken at the time of cancer diagnosis,
hile the plasma samples were collected after at least three lines of palliative
emotherapy. Hence, the mutations found in the tissue biopsy may
iginate from a clone that has been eliminated by the following treatments
5,26]. Also, new mutations may have arisen during the treatment,
plaining our findings in sample 26, where the tissue genotype was not
nfirmed,but a newKRASmutation was securely detected. Secondly, the
GS analysis only securely detects variants present in ≥1% of cfDNA,
hile the ddPCR assays have limits of detection ranging between 0.1%
d 0.3% (Supplementary Table 2). Studies suggest that the ctDNA
actions are low and highly variable (reviewed by Siravegna et al. [27]),
allenging the detection limit of especially the NGS panel used here.
When comparing the results obtained from the ctDNA analyses, we
d that ddPCR is superior in identifying theKRASmutations in ctDNA
hen considering the analysis success rates (NGS: 86%; ddPCR: 100%)gure 2. Comparison of log-transformed B2Mmeasurements from coh
d limits of agreements are found in the figure. (A) Linear regression o
lue of 0.994. (B) Bland-Altman plot of the differences (log(B2M 2 ml)
Downloaded for Anonymous User (n/a) at BS - University of Copen
For personal use only. No other uses without permission. Cd the concordance to tissue genotype. This is in line with other studies
3,28]. When comparing the AFs obtained from the two methods, we
d good correlation between them, with a tendency of higher AFs
tained by ddPCR. If a quantitative measure of ctDNA is needed, this
ding is relevant since the results may depend on the method used. The
st methods for investigating ctDNA and cfDNA are under continuous
aluation (recently reviewed by Sacher et al. [29]). If the mutational
sue status is known and the purpose is to investigate the presence of this
utation in cfDNA, our results suggest that ddPCR is the best method
cause of the higher success rate, lower time demands, and lower
tection limits and costs as compared to the NGS method used here.
owever, in situations where tissue mutational status is unknown or
nnot be recovered, NGS analysis could be preferable for screening the
mples. Also, NGS would reveal more information about the
nstitution of the ctDNA since several genes are often investigated.
Lastly, 92% of the investigated mutations could be recovered in a 10-
ld dilution of the plasma samples compared to the full-volume samples.
nce the ddPCR reaction is expected to be linear, this may not be
rprising. In the present study, extraction of DNA from two different
lumes was not feasible in the cohort of patients with known tissue
notype. Instead, we tested extraction on a different cohort where plasma
as sufficient. We found that in the extraction of cfDNA from 200 μl
asma, the yield was 15% lower than extraction from 2 ml plasma. This
uld have influenced our results in the KRASmutation analysis, and the
covery wouldmost likely have been lower (see Supplementary Table 4).
r complete elucidation of the extraction efficiency for different input
lumes, a larger study is needed.
Despite this, our results indicate that for mCRC low-volume samples
ay often be sufficient for detection of KRAS mutations. This may also
relevant in other solid cancer with high ctDNA shedding.
onclusion
this study, we show that the NGS and ddPCR methods
vestigated have high concordance to tumor genotype (79% and
%). When comparing the methods, we find that ddPCR is superiorort 2. Constant and slope for the regression and mean difference
n measurements from cohort 2. The regression resulted in an R2
− log(B2M 200 μl)).
hagen from ClinicalKey.com by Elsevier on May 27, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
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CRC patients, smaller plasma volumes may often be sufficient for
RAS mutation detection by ddPCR.
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